20-07-2021, 11:09 AM
China's Sinovac COVID-19 vaccine has been approved for emergency use among population aged between 3 and 17 years old, after phase-II clinic trial data suggests it is at least 98.9 percent effective in producing antibodies, a higher efficacy than in population over 18 years old.
The experiment included 180 volunteers within the age group. Three months after vaccination, the production of antibodies among population aged 3 to 17 years old was 98.9 to 100 percent depending on the dosage of the inoculation, the company announced on Monday.
https://www.globaltimes.cn/page/202107/1229068.shtml
The experiment included 180 volunteers within the age group. Three months after vaccination, the production of antibodies among population aged 3 to 17 years old was 98.9 to 100 percent depending on the dosage of the inoculation, the company announced on Monday.
https://www.globaltimes.cn/page/202107/1229068.shtml